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Abstract Azole antifungals inhibit CYP51Al-mediated sterol 
14c~-demethylation a d the mechanism(s) of resistance to such 
compounds in Ustilago maydis were examined. The inhibition of 
growth was correlated with the accumulation of the snbstrate, 
24-methylene-24,25-dihydrolanosterol ( buricol), and depletion 
of ergosterol. Mutants overcoming the effect of azole antifungal 
treatment exhibited a unique phenotype with leaky CYP51A1 
activity which was resistant o inhibition. The results demonstrate 
that alterations at the level of inhibitor binding to the target site 
can produce azole resistance. Similar changes may account for 
fungal azole resistance phenomena in agriculture, and also in 
medicine where resistance has become a problem in immuno- 
compromised patients suffering from AIDS. 
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1. Introduction 
Cytochrome P450s (CYPs) are a superfamily of monooxyge- 
nases involved in various biosynthetic functions as well as being 
central to the initial metabolism of xenobiotics [1]. Fungi pos- 
sess a typical eukaryotic CYP system and the predominant 
P450 of vegetative yeast cells has been observed to be sterol 
14a-demethylase (CYP51A1), an enzyme of the ergosterol bio- 
synthetic pathway [2]. CYP51A1 has been observed to 14a- 
demethylate the sterol substrate via three sequential hydroxyla- 
tions [3] and has become recognised as the target of the azole 
antifungals employed in medicine and agriculture [4]. The 
azoles inhibit fungal CYP51A 1 selectively, binding to the haem 
as a sixth ligand with the N- 1 substituent group interacting with 
the apoprotein [5]. The interaction with the apoprotein deter- 
mines the selectivity, although these compounds can inhibit 
other CYPs at higher concentrations including plant and ani- 
mal sterol 14a-demethylases [6].
Resistance to antimicrobial drugs and pesticides i a common 
observation with widespread use, but problems with the azole 
antifungals emerged first in agriculture [7] and subsequently in 
clinical situations [8]. For the latter the requirement for lifetime 
maintenance for patients uffering AIDS, and who usually suf- 
fer fungal infections, may have increased the probability of 
fungal resistant mutants being selected. Fungal infection is also 
common following therapy after organ transplantation or
chemotherapy where the immune system is suppressed. 
Studies on the model organism Saccharomyces cerevisiae 
*Corresponding author. 
have provided the most comprehensive data on fungal sterol 
requirements and azole resistance. CYP51AI inhibition results 
in the accumulation of substrate (lanosterol) and reduction in 
ergosterol. However, lanosterol has been observed to be subject 
to subsequent metabolism, resulting in the removal of the C4- 
methyl groups, methylation at C24 and 6-hydroxylation by 
sterol A 5'6 desaturase to produce 14c~-methylergosta-8,24(28)- 
dien-3fl,6c~-diol (14c~methyl-3,6-diol) (Fig. 1) [9]. This sterol ac- 
cumulated to a maximum at the point of growth arrest and the 
presence of the 6-hydroxy group in this sterol is thought o 
interfere with sterol/phospholipid hydrogen bonding in the 
membrane. 
The predominant mechanism of azole resistance for S. eere- 
visiae is through a block in sterol A 5'6 desaturase activity [10]. 
This results instead in the accumulation of 14~-methylfeco- 
sterol which can fulfill requirements for growth. Mutant S, ce- 
revisiae strains lacking sterol 14~-demethylase ctivity are also 
azole resistant [11]. However, complementation studies using 
plasmid-bourne sterol 14c~-demethylase have shown resistance 
can be attributed to the suppressor mutations in sterol A 5'6 
desaturase which allow the aerobic growth of such mutants [4]. 
Alteration of the target CYP51A 1 has been proposed previ- 
ously as a possible route to resistance to azole antifungals [4]. 
Such azole resistant mutants have been obtained here from the 
phytopathogen U. maydis. They show a significant difference 
in their mechanism of resistance based on an alteration in the 
target CYP51A1 activity to confer reduced inhibitory effect of 
azole antifungals. 
2. Materials and methods 
2.1. Chemicals 
Unless otherwise indicated all chemical reagents were supplied by 
Sigma U.K. Azoles, [~4C]Triadimenol and fenarimol (a pyrimidine 
sterol 14a-demethylase inhibitor) were supplied by Long Ashton Re- 
search Station, Bristol University, UK. [14C]Mevalonic a id was ob 
tained from Amersham. 
2.2. Culture conditions 
U. maydis strain ATCC 14826 was used. Growth was supported on 
1% (w/v) Difco yeast extract, 2% (w/v) Difco peptone and 2% (w/v) 
glucose (YEPD) liquid medium at 25°C and 150 rpm or on solid YEPD 
plates using 2% (w/v) Difco Bacto-Agar. 
2.3. Antifungal studies 
Unless otherwise specified, all azoles were supplied by Long Ashton 
Research Station. Prochloraz, tebuconazole and the pyrimidine, fenari- 
mol were dissolved in methanol to a stock concentration f 10 -2 M, 
while hexaconazole, triadimenol and dielobutrazol (Zeneca Agro- 
chemicals) were dissolved at the same concentration i  dimethyl sul- 
phoxide (DMSO). Amphotericin B (Sigma UK) and cycloheximide 
(Sigma UK) were dissolved in DMSO to a final stock concentration f 
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Fig. 1. Pathway of sterol formation and alternative pathway after azole 
antifungal treatment. 
1.08 x 10 _3 M. Min imum inhibitory concentrations (MIC) were deter- 
mined for sporidia harvested in late log phase by centrifugation at4000 
rpm and inoculation into 2 ml YEPD medium to give a final concentra- 
tion of 106 cells, m1-1. Triplicate treatments using azole and pyrimidine 
doses between 1 x 10  -4 M and 5 x 10 -8 M, and amphotericin B and 
cycloheximide doses between 5.4 x 10 -5 M and 1.08 x 10 -8 M, and 
between 2 x 10 -6 M and 2 x 10 -9 M, respectively were used. Test MIC 
cultures were incubated for 24 h and 72 h at 25°C and 150 rpm with 
growth assessed by cell counts (haemocytometer), and by colony form- 
ing units per ml. 
2.4. ATCC 14826 growth study 
Experiments to determine the effect of  treatment with time when 
using the MIC of triadimenol were conducted under identical condi- 
tions to those described above except 1 litre cultures in 2 litre flasks were 
employed, with 100 ml of  culture harvested for sterol analysis, dry cell 
weight and cell count determinations. 
2.5. Sterol &olation and analyses 
Extraction of non-saponifable sterols followed the method outlined 
by Woods et al. [12] with GC-MS analyses conducted as described by 
Loeffler et al. [13]. Peak analysis and identification were realised 
through reference to current literature [13-16] for relative retention 
time (RRT) values and fragmentation ion patterns. 
2.6. Cell free sterol biosynthesis analyses 
Assay of azole inhibition of  ergosterol biosythesis was using the cell 
free biosynthesis system described extensively in the literature [17,18]. 
500 ml flasks containing 200 ml YEPD were inoculated with strains to 
a concentration of 106 sporidia per ml and grown at 25°C at 150 rpm. 
Cells were harvested in late log phase by centrifugation (4000 rpm for 
10 min) and resuspended in 25 ml 0.2 M phosphate buffer containing 
140 ml 0.2 M KHzPO4, 360 ml 0.2 M KzHPO 4, 20% (v/v) glycerol and 
1 mM EDTA (pH 6.8). Cell disruption was achieved using a Braun 
MSK homogeniser with three 30 s disruptions. Cell free extracts were 
harvested by centrifugation at4000 rpm for 10 min. 0.5 ml of co-factor 
mix (20 mg NADPH,  18 mg NAD,  17 mg NADR 55 mg ATP, 20 mg 
glutathione, 30 mg glucose-6-phosphate dissolved in 1 ml phosphate 
buffer) was added to 9.5 ml of supernatant with 20/11 1 M magnesium 
chloride and 10 ¢tl 1 M manganese chloride. To 1 ml of the above mix 
triadimenol was added at varying concentrations. 10/~1 [14C]mevalonic 
acid (specific activity 53 mCi/mmol) was added to each sample and 
incubated at 25°C for 2 h. Sterol extraction of  non-saponifiable sterols 
was conducted as described above. 
Sterol identification was achieved through thin layer chromatogra- 
phy (Merck) with solvent as a 4 : 1 mix of cyclohexane : diethyl ether 
with ergosterol and lanosterol co-run as standards. Autoradiograms 
were developed over 7 days at -80°C and radioactivity incorporated 
into ergosterol quantified on a Beckman LS 1801 scintillation counter. 
2. 7. Preparation of mierosomal fraction 
Sporidia of U. mayd& strain ATCC 14826 and Tri R-~, Tri R-2 and Tri R-3 
in the logarthmic phase of  growth were inoculated (106 cells, ml -~) into 
liquid YEPD (1 litre) in 2 litre flasks and incubated at 25°C and 110 
rpm until a cell density of 5 × 107 cells .ml -~ was reached. Preparation 
of the microsomal fraction from protoplasts of U maydis followed the 
procedure outlined by Carelli et al. [19]. Protein content was estimated 
using the procedure outlined by Lowry et al. [20]. 
2.8. Accumulation of triadimenol 
Cells were inoculated into 100 ml YEPD in 250 ml flasks at l06 
cells/ml and incubated at 25°C and 150 rpm until growth reached 
stationary phase. Cells were harvested by centrifugation at 4000 rpm, 
washed in phosphate buffer, pH 7.0 (phosphate buffer tablets pH 7.0, 
BDH) and resuspended in 1 ml phosphate buffer, pH 7.0 at a final 
concentration of 2 × 109cells/ml. [~4C]Triadimenol was added to a con- 
centration o f  1 × 10 -5 M from a 22.2/ICi/mg stock and incubated for 
1 h at 25°C and shaken every 10 rain. Cells were harvested and washed 
in 5 ml cold triadimenol (5 × 10 -5 M). Cells were re-harvested onto 
Whatman no.1 filters by vacuum filtration. This wash was repeated 
Table 1 
Percentage sterol compositions of  U. maydis ATCC 14826 after treatment with the azole fungicide triadimenol at the MIC" 
Sterol Time (hours) 
0 ct b 0 0.5 1 3 6 9 12 18 24 36 36 ct b 
Ergostatetraenol 3.6 3.5 3.0 2.9 - 1.8 2.0 - 2.3 
Ergosta-8,22-dienol 0.6 1.0 1.6 1.7 . . . .  1.9 2.7 
Ergosterol 51.6 55.0 39.9 39.9 30.6 28.6 18.2 12.9 10.7 6.0 1.7 55.6 
Ergosta-7,22-dienol - 1.0 2.2 1.5 . . . .  4.2 
14c~-Methyl fecosterol 3.2 1.2 1.9 - - 11.8 12.3 11.6 17.8 18.2 - 
Ergosta-5,7-dienol 27.4 25.8 17.8 18.2 4.9 11.2 7.8 5.1 5.5 3.1 0.3 28.2 
Ergost-7-enol 5.6 6.0 3.0 - - 0.2 - - 2.5 1.9 2.3 
Obtusifoliol - 3.8 5.8 14.6 11.9 25.9 32.4 23.8 33.4 38.3 0.5 
14c~-Methyl-3,6-dioF - . . . . .  5.6 5.8 14.2 0.5 
Eburicol 1.9 2.2 21.8 25.6 43.7 42.4 31.2 34.0 36.6 29.3 23.5 1.9 
Unidentified sterols 6.1 4.3 5.0 4.2 6.2 5.9 3.1 1.3 6.2 2.1 0.1 1.1 
Dry cell weight (mg) 54 56 55 58 65 85 90 100 100 100 100 296 
Key: a = 1 × 10 -5 M; ct b = untreated control; c = 14~-methylergosta-8,24(28)-diene-3fl,6~-diol. 
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Table 2 
Comparison of minimum inhibitory concentrations for various antifun- 
gals in parent and mutant isolates 
Drug type ATCC TRI R-1 TRI R-2 TRI R-3 
14826 
Azoles (pM) 
Diclobutrazol 1 10 50 50 
Triadimenol 1 5 10 l 0 
Tebuconazole 0.1 0.5 1 1 
Procholaz 10 50 100 50 
Hexaconazole 1 10 50 50 
Other (/zM) 
Fenarimol 5 10 30 50 
Amphotericin B 0.6 0.9 1.1 1.1 
Cycloheximide 0.2 0.2 0.2 0.2 
three times. Cells and filters were baked at 80°C until dry. Counts per 
minute were measured on a Beckman LS 1801 scintillation counter. 
Cellular content was calculated in triplicate as pmoles triadimenol/ 
109cells. 
3. Results 
3.1. Analysis of triadimenol induced growth arrest of U. maydis 
U. maydis treated with triadimenol has been employed here 
as a comparative experimental system to investigate the general 
relevance of 14c~-methyl-3,6-diol t  azole induced growth ar- 
rest. Treatment of this phytopathogen with the minimum inhib- 
itory concentration of triadimenol resulted in an overall accu- 
mulation of 14~-methyl sterols with a concomitant decrease in 
the desmethyl sterols (Table 1) which is in agreement with 
previous studies [14,21]. 
Ergosterol concentration was observed to decrease across 
the treatment period from an initial level of 55% to a final 
concentration of 1.7% at 24 h. Similar decreases of other des- 
methyl sterols were also observed such as that of ergosta-5,7- 
dienol. Azole treatment resulted in the accumulation of 14c~- 
methyl sterols, predominately eburicol and obtusifoliol. Eburi- 
col content rose sharply from an untreated level of 2.2% of total 
sterol to a peak of 43.7% at the third hour sample, whereafter 
the level decreased to 23.5% of total sterol at 36 h. Obtusifoliol 
showed increased accumulation across the treatment study, 
rising from 0% to 38.3% of total sterol at the thirty-sixth our 
sample. 14~-Methyl-3,6-diol remained undetected until the 
eighteenth our, and thereafter increased upto a final relative 
concentration of 14.2%. 
Growth arrest of ATCC 14826 occurred by the twelfth hour 
as shown by dry cell weight and cell counts (Table 1). At this 
point the concentration of ergosterol was 12.9%, eburicol and 
obtusifoliol were at 34.0% and 32.4%, respectively, and 14~- 
methyl-3,6-diol was not observed. 
3.2. Isolation of azole resistant mutants 
Screening for mutants used 106 cells ATCC 14826 on 20 ml 
solid YEPD in 9 cm petri dishes. Triadimenol concentrations 
of five- and ten-fold above the MIC of ATCC 14826, yielded 
three triadimenol resistant mutants with a frequency of 10 -8. 
Cross-resistance to the azoles diclobutrazol, hexaconazole, pro- 
cholaz and tebuconazole and the pyrimidine fenarimol was 
observed for the mutants Tri R-~, Tri R2 and Tri R3 at varying 
levels (Table 2). Sensitivities to other classes of antifungal drugs 
were investigated and for amphotericin B and cycloheximide 
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similar sensitivities to values for ATCC 14826 were observed. 
ATCC 14826 and the azole mutants all grew at the same rate 
with a doubling time of 2.5 h when untreated. 
3.3. Cellular content of [~4C]triadimenol 
In order to examine the possible involvement of uptake and/ 
or efflux mechanisms in the azole resistance of these mutants, 
the cellular content of triadimenol was examined. From tripli- 
cate treatments imilar values of uptake for each mutant and 
the parent strain were observed (Table 3). 
3.4. Sterol analysis of Tri R-I, Tri R-2 and Tri R-3 
Sterol profiles of each mutant were determined in the absence 
of azole (Table 4). The relative percentage compositions of 
14c~-methyl sterols were 62.2%, 80% and 49.9% and for ergo- 
sterol were 29.1%, 16.1% and 39.7% for Tri R-l, Tri R-2 and Tri R-3 
respectively compared to the 14c~-methyl sterol content of 5.1% 
and an ergosterol relative concentration of 55.0% for ATCC 
14826. Under triadimenol treatment for 24 h at the MIC dose 
for ATCC 14826, the relative percentage compositions of er- 
gosterol decreased in Tri R-~ (8.2%) and Tri R-3 (31.2%). A greater 
reduction was observed when treating with the MIC of each 
mutant, where the relative concentration of ergosterol was 3.6% 
and 10.2%, respectively (Table 4). Tri R-2 showed little variation 
in ergosterol content under treatment or total 14c~-methyl sterol 
concentrations at either treatment dose (Table 4). 
3.5. Levels of sterol P45014~-am from ATCC 14826, Tri R-I, Tri R-2 
and Tri R-~ 
The microsomal fractions produced a maximum at 448 nm 
in reduced carbon monoxide difference spectra for ATCC 
14826 and each mutant similar to that reported previously for 
U. maydis [19], Specific contents of 20(+0.3) pmol .mg -1, 
21(+0.5) pmol-mg -l, 20(+ 1.0) pmol .mg -1 and 
20(_+0.3) pmol 'mg -~ for ATCC 14826, Tri R~, Tri R-2, and Tri R-3 
were determined, respectively (Table 3). 
3.6. Inhibition of sterol P45014c~-am ctivity in vitro 
The in vitro sterol biosynthesis for parent and mutants were 
compared under triadimenol treatment. IC50 (concentration re- 
quired to inhibit ergosterol biosynthesis by 50%) was deter- 
mined by following ergosterol biosynthesis from [14C]mevalonic 
acid [17]. The sterol 14c~-demethylase of each mutant was ob- 
served to be resistant (Table 3). Tri rt-I required five fold more 
triadimenol and Tri R2 and Tri R-3 required ten fold the concen- 
tration of triadimenol for equivalent inhibition to that observed 
for ATCC 14826. 
Table 3 
Comparison of untreated growth rates, cellular content of [~4C]triadi- 
menol, specific contents of P450 and IC50 values for in vitro inhibition 
of ergosterol biosynthesis by triadimenol in parent and mutant isolates 
ATCC Tri R-I Tri R-2 Tri R-3 
14826 
pmol [14C]triadi- 
menol/109 cells 12 + 0.5 13.5 + 0.1 14 + 0.3 12 + 0.1 
pmol P450/mg mi- 
crosomal protein 20 + 0.3 21 + 0.5 20 + 1.0 20 + 0.3 
IC~0 (pM) 0.08 + 0.003 0.3 + 0.03 0.8 + 0.03 0.8 + 0.03 
Doubling time (h) 2.5 2.5 2.5 2.5 
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Table 4 
Sterol profiles of ATCC 14826 in comparison to mutant isolates 
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Sterol Relative percentage sterol composition 
ATCC TRI R-j TRI TM TRI R-lb TRI R-2 TRI R-2a TRI R-2c TRI R-3 TRI R-3a TRI R-3b 
14826 
Ergosta-tetraenol 2.8 7.9 - 0.7 1.4 Trace 5.0 Trace Trace 
Ergosterol 55.6 29.1 8.2 3.6 16.1 22.9 20.2 39.7 31.2 10.2 
14~-Methylfecosterol 20.8 7.1 50.7 15.3 5.5 5.7 10.3 11.6 32.4 
Ergosta-5,7-dienol 28.2 8.6 - - 5.3 6.4 5.7 9.9 - 
Obtusifoliol 21.7 18.5 17.4 31.0 18.8 14.4 29.4 24.1 19.2 
14~-Methyl-3,6-diol a 0.5 1.8 5.5 19.5 20.0 21.8 2.1 4.9 
Eburicol 1.9 1.8 66.2 22.8 15.5 24.1 27.5 4.9 20.4 33.2 
M ÷ = 552 - - - 4.9 - 
Unidentified sterols 11.0 8.3 0.0 0.0 6.8 2.0 4.0 0.1 0.6 0.0 
Key: a = 1 x 10 -6 M triadimenol; b __-- 5 X 10 -6 M triadimenol; ~= 1 x 10 -5 M triadimenol; and d = 14a-methylergosta-8,24(28)-diene-3fl,6a-diol. 
4. Discussion 
CYP51A1 is essential for aerobic growth of yeast [22], and 
probably in fungi generally. Studies on this protein and its 
inhibition are of practical and academic significance and enan- 
tiomers of the numerous drugs and pesticides are proving useful 
tools with which to undertake molecular modelling studies 
[4,23]. The discovery here that mutations in CYP51A1 can 
result in reduced inhibition by azole antifungals will provide 
further important information with which to understand the 
active site topology. 
The consequences of inhibition of the enzyme is the reduc- 
tion of ergosterol and accumulation of 14~-methylated sterols. 
However, one 14~-methylated sterol does satisfy the growth 
requirements of S. cerevisiae. 14~-Methylfecosterol accumu- 
lates in sterol A 5'6 desaturase mutants under azole treatment 
instead of 14-methyl-3,6-diol [10] and results in azole resistance. 
This mechanism of resistance was not apparent in the U. maydis 
studies reported here in which mutants were challenged irectly 
with azole antifungal, but a possible leaky sterol/[5(6) desaturase 
mutant which is azole resistant is the subject of further investi- 
gation. An examination of the selective pressure under which 
the U. maydis was placed indicated the period of growth arrest 
occurred without accumulation of 14-methyl-3,6-diol. 
The frequency with which sterol A 5'6 desaturase mutations 
and azole resistance arises in S. cerevisiae is approximately 10 -5 
(unpublished observations). However, resistant mutants oc- 
curred here with a frequency of approximately 10 -s suggesting 
mutagenesis at a limited number of nucleotide positions could 
cause resistance. The biochemical characterisation f the azole 
resistant mutants howed they were not associated with degra- 
dation of the antifungal or with altered uptake or efflux. The 
latter has been associated with resistance in some strains of 
Candida albicans [24] and Penicillium italicum [25]. Similarly, 
the specific content of P450 remained unaltered in each mutant 
in comparison to the parent strain, ATCC 14826. This indi- 
cated that resistance was not as a result of increased P450 
expression, which has previously been linked with azole re- 
sistance in tobacco [26]. 
The lesion(s) resulting in resistance in the three mutants of 
U. maydis was identified as being in CYP51A1. The mutants 
showed altered patterns of sterol biosynthesis in vivo with the 
accumulation of increased quantities of the CYP51A1 sub- 
strate, 24-methylene-24(25)-dihydrolanosterol. Coupled to the 
observation of leaky CYP51A1 activity was the observation 
that in vitro inhibition of sterol 14~-demethylase in the mutants 
required increased concentrations of azole antifungal when 
compared to the wild-type. Together this information indicates 
a change in the apoprotein of CYP51A1 altering the activity, 
but reducing the ability of azole antifungals to inhibit the en- 
zyme. Other possible changes which could produce a leaky 
sterol 14~-demethylase would not account for the relative re- 
sistance of the in vitro activity to azole inhibition. 
Ergosterol was also at a reduced level in all the mutants, but 
not such that growth was altered (Table 3). An important factor 
concerning resistant strains found in agriculture is the require- 
ment for robust growth under environmental conditions and 
the phenotype of the mutants tudied here would seem to satisfy 
this requirement. As the mutants till contain ergosterol super- 
ficial classification might also identify them as being wild-type. 
Examination of  azole resistance in agricultural, or clinical iso- 
lates, should be made with this information in mind and de- 
tailed biochemical investigation may be needed to confirm an 
alteration in CYP51A1. Our efforts are now concerned with 
isolating CYP51A1 from wild-type and azole resistant mutants. 
Nucleotide sequence comparison and site-directed mutation 
studies will be required to confirm the alterations in the protein 
causing resistance and should provide important information 
to assist our understanding of the structure of this protein and 
possible routes to combat resistance. 
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